These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 33001143)

  • 1. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.
    Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
    JAMA Oncol; 2020 Nov; 6(11):1766-1772. PubMed ID: 33001143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
    André T; Berton D; Curigliano G; Sabatier R; Tinker AV; Oaknin A; Ellard S; de Braud F; Arkenau HT; Trigo J; Gravina A; Kristeleit R; Moreno V; Abdeddaim C; Vano YA; Samouëlian V; Miller R; Boni V; Torres AA; Gilbert L; Brown J; Dewal N; Dabrowski C; Antony G; Zografos E; Veneris J; Banerjee S
    JAMA Netw Open; 2023 Nov; 6(11):e2341165. PubMed ID: 37917058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
    Oaknin A; Gilbert L; Tinker AV; Brown J; Mathews C; Press J; Sabatier R; O'Malley DM; Samouelian V; Boni V; Duska L; Ghamande S; Ghatage P; Kristeleit R; Leath C III; Guo W; Im E; Zildjian S; Han X; Duan T; Veneris J; Pothuri B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35064011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
    Mirza MR; Chase DM; Slomovitz BM; dePont Christensen R; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Hanker LC; Stuckey A; Boere I; Gold MA; Auranen A; Pothuri B; Cibula D; McCourt C; Raspagliesi F; Shahin MS; Gill SE; Monk BJ; Buscema J; Herzog TJ; Copeland LJ; Tian M; He Z; Stevens S; Zografos E; Coleman RL; Powell MA;
    N Engl J Med; 2023 Jun; 388(23):2145-2158. PubMed ID: 36972026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study.
    Berton D; Pautier P; Lorusso D; Gennigens C; Gladieff L; Kryzhanivska A; Bowman J; Tian C; Cornfeld M; Van Gorp T
    Gynecol Oncol; 2024 Jul; 186():191-198. PubMed ID: 38824752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer.
    Konstantinopoulos PA; Gockley AA; Xiong N; Krasner C; Horowitz N; Campos S; Wright AA; Liu JF; Shea M; Yeku O; Castro C; Polak M; Lee EK; Sawyer H; Bowes B; Moroney J; Cheng SC; Tayob N; Bouberhan S; Spriggs D; Penson RT; Fleming GF; Nucci MR; Matulonis UA
    JAMA Oncol; 2022 Sep; 8(9):1317-1322. PubMed ID: 35900726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dostarlimab in the treatment of mismatch repair deficient recurrent or advanced endometrial cancer.
    Shukla S; Patel H; Chen S; Sun R; Wei L; Chen ZS
    Cancer Pathog Ther; 2024 Jul; 2(3):135-141. PubMed ID: 39027143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.
    Oaknin A; Tinker AV; Gilbert L; Samouëlian V; Mathews C; Brown J; Barretina-Ginesta MP; Moreno V; Gravina A; Abdeddaim C; Banerjee S; Guo W; Danaee H; Im E; Sabatier R
    Future Oncol; 2021 Oct; 17(29):3781-3785. PubMed ID: 34427115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world dostarlimab use in advanced/recurrent endometrial cancer in France.
    Rodrigues M; Eberst L; Follana P; Gauthier L; Jacquemin V; Tessier C; El Mouaddin N; Boudier P; Fiteni F; Angeli E; Roche S; Delanoy N; Sabatier R; Flippot R; de la Motte Rouge T
    Bull Cancer; 2023 Oct; 110(10):1041-1050. PubMed ID: 37659907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
    Cercek A; Lumish M; Sinopoli J; Weiss J; Shia J; Lamendola-Essel M; El Dika IH; Segal N; Shcherba M; Sugarman R; Stadler Z; Yaeger R; Smith JJ; Rousseau B; Argiles G; Patel M; Desai A; Saltz LB; Widmar M; Iyer K; Zhang J; Gianino N; Crane C; Romesser PB; Pappou EP; Paty P; Garcia-Aguilar J; Gonen M; Gollub M; Weiser MR; Schalper KA; Diaz LA
    N Engl J Med; 2022 Jun; 386(25):2363-2376. PubMed ID: 35660797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
    O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
    J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab.
    Kristeleit R; Mathews C; Redondo A; Boklage S; Hanlon J; Im E; Brown J
    Int J Gynecol Cancer; 2022 Aug; 32(10):1250-7. PubMed ID: 35973737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
    Patnaik A; Weiss GJ; Rasco DW; Blaydorn L; Mirabella A; Beeram M; Guo W; Lu S; Danaee H; McEachern K; Im E; Sachdev JC
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):93-103. PubMed ID: 34750637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.
    Antill Y; Kok PS; Robledo K; Yip S; Cummins M; Smith D; Spurdle A; Barnes E; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Andrews J; Stockler MR; Mileshkin L;
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Exceptional Response to Dostarlimab in Mismatch Repair Deficient, Microsatellite Instability-High and Platinum Refractory Endometrial Cancer.
    Bartoletti M; Giorda G; Viel A; Fornasarig M; Zdjelar A; Segatto E; Sorio R; Corsetti S; Scalone S; Nicoloso MS; Pivetta T; Lucia E; Clemente N; Palazzari E; Canzonieri V; Puglisi F
    Curr Oncol; 2022 Jul; 29(8):5209-5212. PubMed ID: 35892982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer.
    Kasherman L; Ahrari S; Lheureux S
    Future Oncol; 2021 Mar; 17(8):877-892. PubMed ID: 33251877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.
    Powell MA; Bjørge L; Willmott L; Novák Z; Black D; Gilbert L; Sharma S; Valabrega G; Landrum LM; Gropp-Meier M; Stuckey A; Boere I; Gold MA; Segev Y; Gill SE; Gennigens C; Sebastianelli A; Shahin MS; Pothuri B; Monk BJ; Buscema J; Coleman RL; Slomovitz BM; Ring KL; Herzog TJ; Balas MM; Grimshaw M; Stevens S; Lai DW; McCourt C; Mirza MR
    Ann Oncol; 2024 Aug; 35(8):728-738. PubMed ID: 38866180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
    Ott PA; Bang YJ; Berton-Rigaud D; Elez E; Pishvaian MJ; Rugo HS; Puzanov I; Mehnert JM; Aung KL; Lopez J; Carrigan M; Saraf S; Chen M; Soria JC
    J Clin Oncol; 2017 Aug; 35(22):2535-2541. PubMed ID: 28489510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
    Dioun S; Chen L; Melamed A; Gockley A; St Clair CM; Hou JY; Khoury-Collado F; Hur C; Elkin E; Accordino M; Hershman DL; Wright JD
    BJOG; 2023 Jan; 130(2):214-221. PubMed ID: 36330672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
    Moreno V; Roda D; Pikiel J; Trigo J; Bosch-Barrera J; Drew Y; Kristeleit R; Hiret S; Bajor DL; Cruz P; Beck JT; Ghosh S; Dabrowski C; Antony G; Duan T; Veneris J; Zografos E; Subramanian J
    Clin Lung Cancer; 2022 Nov; 23(7):e415-e427. PubMed ID: 35729005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.